FDA approves first adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Gu érin unresponsive non-muscle invasive bladder cancer
FDA approves first adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Gu érin unresponsive non-muscle invasive bladder cancer
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: FDA Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | Gene Therapy | Genetics